Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (5)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Higgins, P. G.
Right arrow Articles by Schmitz, F.-J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Higgins, P. G.
Right arrow Articles by Schmitz, F.-J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?


Journal of Antimicrobial Chemotherapy (2002) 50, 299-301
© 2002 The British Society for Antimicrobial Chemotherapy

Correspondence

Antimicrobial susceptibility of imipenem-resistant Pseudomonas aeruginosa

P. G. Higgins1,*, A. C. Fluit2, D. Milatovic2, J. Verhoef2 and F.-J. Schmitz1

1 Institute for Medical Microbiology and Virology, Universitätsklinikum Düsseldorf, Universitätsstraße 1, Geb. 22.21, 40225 Düsseldorf, Germany; 2 Eijkman-Winkler Institute for Medical Microbiology, University Medical Center Utrecht, Utrecht, The Netherlands

The first 10% of the full text of this article appears below.

Sir,

In a recent leading article by Giamarellou,1 the prescribing guidelines for Pseudomonas aeruginosa infections were discussed. It was stated that the anti-pseudomonal drugs available for the clinician include the aminoglycosides, ureidopenicillins, ceftazidime, the carbapenems and ciprofloxacin. Given the propensity for this organism to become drug resistant, a worrying question for the clinician arises: what alternatives exist if one of these major anti-pseudomonal drugs fails?

Recent surveillance studies with P. aeruginosa have not differentiated . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 J Antimicrob ChemotherHome page
R. R. Reinert, D. E. Low, F. Rossi, X. Zhang, C. Wattal, and M. J. Dowzicky
Antimicrobial susceptibility among organisms from the Asia/Pacific Rim, Europe and Latin and North America collected as part of TEST and the in vitro activity of tigecycline
J. Antimicrob. Chemother., November 1, 2007; 60(5): 1018 - 1029.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Microbiol.Home page
M. P. Crespo, N. Woodford, A. Sinclair, M. E. Kaufmann, J Turton, J. Glover, J. D. Velez, C. R. Castaneda, M. Recalde, and D. M. Livermore
Outbreak of Carbapenem-Resistant Pseudomonas aeruginosa Producing VIM-8, a Novel Metallo-{beta}-Lactamase, in a Tertiary Care Center in Cali, Colombia
J. Clin. Microbiol., November 1, 2004; 42(11): 5094 - 5101.
[Abstract] [Full Text] [PDF]